Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Analyst Ratings
Moderate Buy
3 Buy
2 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
SGMO Stock 12 Month Forecast
Average Price Target
$4.75
▲(813.46% Upside)
| Highest Price Target$10.00 | Average Price Target$4.75 | Lowest Price Target$2.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$10
Buy
1823.08%
Upside
Reiterated
08/12/25
Sangamo Biosciences: Poised for Significant Value Creation with Promising Clinical Trials and Strategic PartnershipsWe assess Sangamo using a discounted cash flow (DCF)-based and sum-of-the-parts (SOTP)-based methodology. We assign probability of success to isaralgagene civaparvovec (SB-920) in Fabry disease of 85%. We model a build in continued milestone payments and revenues tied to Sangamo's SIFTER / ZFP platforms starting in 2025, leading to a moderate present value. We include a gross capital raise of $150 million in 2026E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x.
TD Cowen
―
Buy
―
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy RatingWe estimate pro forma current cash of ~$29M may bridge OpEx into 4Q25. SGMO continues to engage in partnership talks for BLA-ready giro in HemeA. Mgmt maintained guidance for FY25 GAAP FY25 non-GAAP OpEx of $124- 145M. SGMO will present additional Ph1/2 '920 Fabry data at ICIEM (Sept 2 - Sept 6; Kyoto). First Ph1/2 iSFN data is on track for 4Q26.
Barclays
$5
Buy
861.54%
Upside
Reiterated
08/08/25
RBC Capital
$2
Hold
284.62%
Upside
Reiterated
08/07/25
Wells Fargo
$2
Hold
284.62%
Upside
Reiterated
06/25/25
Jefferies
$2→$1.5
Buy
188.46%
Upside
Reiterated
05/13/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$10
Buy
1823.08%
Upside
Reiterated
08/12/25
Sangamo Biosciences: Poised for Significant Value Creation with Promising Clinical Trials and Strategic PartnershipsWe assess Sangamo using a discounted cash flow (DCF)-based and sum-of-the-parts (SOTP)-based methodology. We assign probability of success to isaralgagene civaparvovec (SB-920) in Fabry disease of 85%. We model a build in continued milestone payments and revenues tied to Sangamo's SIFTER / ZFP platforms starting in 2025, leading to a moderate present value. We include a gross capital raise of $150 million in 2026E, which could dilute existing shareholders. We employ a 12% discount rate and a terminal multiple of 6.0x.
TD Cowen
―
Buy
―
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy RatingWe estimate pro forma current cash of ~$29M may bridge OpEx into 4Q25. SGMO continues to engage in partnership talks for BLA-ready giro in HemeA. Mgmt maintained guidance for FY25 GAAP FY25 non-GAAP OpEx of $124- 145M. SGMO will present additional Ph1/2 '920 Fabry data at ICIEM (Sept 2 - Sept 6; Kyoto). First Ph1/2 iSFN data is on track for 4Q26.
Barclays
$5
Buy
861.54%
Upside
Reiterated
08/08/25
RBC Capital
$2
Hold
284.62%
Upside
Reiterated
08/07/25
Wells Fargo
$2
Hold
284.62%
Upside
Reiterated
06/25/25
Jefferies
$2→$1.5
Buy
188.46%
Upside
Reiterated
05/13/25
Best Analysts Covering Sangamo Biosciences
1 Month
xxx
Success Rate
8/17 ratings generated profit
Average Return
-2.95%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of -2.95% per trade.
3 Months
xxx
Success Rate
8/17 ratings generated profit
Average Return
+8.00%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of +8.00% per trade.
1 Year
Success Rate
8/17 ratings generated profit
Average Return
+22.69%
reiterated a buy rating 23 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 47.06% of your transactions generating a profit, with an average return of +22.69% per trade.
2 Years
xxx
Success Rate
6/17 ratings generated profit
Average Return
-21.87%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 35.29% of your transactions generating a profit, with an average return of -21.87% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
SGMO Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
3
8
8
7
4
Buy
3
5
6
5
3
Hold
7
8
9
13
21
Sell
3
5
6
3
1
Strong Sell
0
0
0
0
0
total
16
26
29
28
29
Each month's total comprises the sum of three months' worth of ratings.
SGMO Financial Forecast
SGMO Stock Forecast FAQ
What is SGMO’s average 12-month price target, according to analysts?
Based on analyst ratings, Sangamo Biosciences’s 12-month average price target is 4.75.
What is SGMO’s upside potential, based on the analysts’ average price target?
Sangamo Biosciences has 813.46% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is SGMO a Buy, Sell or Hold?
Sangamo Biosciences has a consensus rating of Moderate Buy which is based on 3 buy ratings, 2 hold ratings and 0 sell ratings.
What is Sangamo Biosciences’s price target?
The average price target for Sangamo Biosciences is 4.75. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $2.00. The average price target represents 813.46% Increase from the current price of $0.52.
The highest analyst price target is $10.00 ,the lowest forecast is $2.00. The average price target represents 813.46% Increase from the current price of $0.52.
What do analysts say about Sangamo Biosciences?
Sangamo Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of SGMO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.